65,437 trials
HIV-1-infection
Primary: Number of Participants With RNA <50 Copies/mL at 48 Weeks — 19 Participants — p=<0.05
Stroke
Primary: Score on Action Research Arm Test (ARAT) — 13.46; 14.82; 13.09 score on a scale — p=0.24
Dysphagia · Stroke
Primary: To Assess Changes in Penetration and Aspiration — -0.4; -0.8; -0.8 score on a scale
HIV Infections
Primary: To Compare the Phase 1 Viral Decay Rates Between LPV/r + RAL vs. EFV/TDF/FTC Treatment Combinations. — 0.47; 0.55 log(10)/day
Pain
Primary: Comparison of Functional Connectivity Changes of the DLPFC Before and After tDCS Stimulation — -0.11; -0.09; 0.08; -0.13 Fisher Z value
Hip Fractures · Femoral Neck Fractures
Primary: Number of Participants With Revision Surgery — 57; 60 Participants
Opioid-Related Disorders
Primary: Number of Participants With Opioid Abstinence at 8 Weeks — 0; 1 Participants — p=0.44
Parkinson's Disease
Primary: Attention Network Effects
Breast Cancer · Infertility
Primary: Mature Oocyte Yield — 5.1; 7.9 oocytes — p=0.31
Primary Mitochondrial Disease
Primary: Distance Walked on the 6-minute Walk Test (6MWT) by Visit — 394.1; 378.2 meters
Bleeding · Implants · Breakthrough Bleeding
Primary: Total Number of Consecutive Bleeding-free Days in First 30 Days From Day 1 of First Treatment (TX1) — 18.5; 8.7 days
Acute Pyelonephritis
Primary: Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) — 68; 15; 15; 16 Participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c — -1.71; -1.20; -1.16 Percentage points of HbA1c — p=<0.0001
Atrial Septal Defect
Primary: Number of Participants Who Experienced Adverse Events Possibly Related to Study Intervention — 0; 6 Participants
Whooping Cough
Primary: Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (During Third Trimester of Pregnancy) or Not Exposed to Any…